CO2017006640A2 - Metodos para el desarrollo y uso de unidades de micro-agregado de funcion celular polarizada en aplicaciones de tejido usando lgr4, lgr5 y lgr 6 que expresan celulas madre epiteliales - Google Patents
Metodos para el desarrollo y uso de unidades de micro-agregado de funcion celular polarizada en aplicaciones de tejido usando lgr4, lgr5 y lgr 6 que expresan celulas madre epitelialesInfo
- Publication number
- CO2017006640A2 CO2017006640A2 CONC2017/0006640A CO2017006640A CO2017006640A2 CO 2017006640 A2 CO2017006640 A2 CO 2017006640A2 CO 2017006640 A CO2017006640 A CO 2017006640A CO 2017006640 A2 CO2017006640 A2 CO 2017006640A2
- Authority
- CO
- Colombia
- Prior art keywords
- lgr
- applications
- lgr4
- lgr5
- development
- Prior art date
Links
- 101150081517 LGR4 gene Proteins 0.000 title 1
- 230000003915 cell function Effects 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/362—Skin, e.g. dermal papillae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086526P | 2014-12-02 | 2014-12-02 | |
| US14/954,335 US10926001B2 (en) | 2014-12-02 | 2015-11-30 | Methods related to minimally polarized functional units |
| PCT/US2015/063114 WO2016089825A1 (en) | 2014-12-02 | 2015-12-01 | Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017006640A2 true CO2017006640A2 (es) | 2017-11-21 |
Family
ID=56078499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0006640A CO2017006640A2 (es) | 2014-12-02 | 2017-06-30 | Metodos para el desarrollo y uso de unidades de micro-agregado de funcion celular polarizada en aplicaciones de tejido usando lgr4, lgr5 y lgr 6 que expresan celulas madre epiteliales |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US10926001B2 (enExample) |
| EP (2) | EP3227431B1 (enExample) |
| JP (3) | JP6791854B2 (enExample) |
| KR (5) | KR20210043024A (enExample) |
| CN (1) | CN107250348B (enExample) |
| AU (3) | AU2015355187C1 (enExample) |
| BR (1) | BR112017011808A2 (enExample) |
| CA (1) | CA2969707C (enExample) |
| CO (1) | CO2017006640A2 (enExample) |
| CR (1) | CR20170296A (enExample) |
| EA (1) | EA201791125A1 (enExample) |
| GB (2) | GB2549872A (enExample) |
| HK (1) | HK1250515A1 (enExample) |
| IL (2) | IL252613B (enExample) |
| MX (2) | MX2017007243A (enExample) |
| MY (1) | MY184931A (enExample) |
| NZ (2) | NZ755260A (enExample) |
| PH (1) | PH12017501009B1 (enExample) |
| SG (2) | SG10201914058QA (enExample) |
| WO (1) | WO2016089825A1 (enExample) |
| ZA (1) | ZA201703907B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3595440A2 (en) * | 2017-03-14 | 2020-01-22 | Juno Therapeutics, Inc. | Methods for cryogenic storage |
| CR20200366A (es) * | 2018-01-26 | 2020-10-05 | Polarityte Inc | Sustrato acelarante de biomaterial con interfaz compuesta |
| AU2019212976A1 (en) * | 2018-01-26 | 2020-07-23 | Polarityte, Inc. | Complex living interface-coordinated self-assembling materials (CLICSAM) |
| FR3082123B1 (fr) | 2018-06-07 | 2020-10-16 | Urgo Rech Innovation Et Developpement | Pansement cellularise et son procede de fabrication |
| JP2024006681A (ja) * | 2022-07-04 | 2024-01-17 | 学校法人近畿大学 | 生体材料 |
| WO2025166131A1 (en) * | 2024-02-01 | 2025-08-07 | Board Of Regents, The University Of Texas System | Compositions and methods for treating bone and muscle injuries |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040126881A1 (en) * | 2002-09-06 | 2004-07-01 | Vincent Ronfard | Fibrin cell supports and methods of use thereof |
| WO2006008009A2 (en) | 2004-07-23 | 2006-01-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6) |
| US20060154365A1 (en) | 2004-08-30 | 2006-07-13 | Anthony Ratcliffe | Cultured three dimensional tissues and uses thereof |
| EP1942957B1 (en) * | 2005-10-27 | 2012-07-11 | Coloplast A/S | Biodegradable scaffold with ecm material |
| WO2008008009A1 (en) | 2006-07-13 | 2008-01-17 | St. Jude Medical Ab | Medical information management in a patient information hub system |
| US8366723B2 (en) | 2006-08-03 | 2013-02-05 | Rassman Licensing, Llc | Hair harvesting device and method with localized subsurface dermal fluid insertion |
| US7998737B2 (en) | 2006-09-12 | 2011-08-16 | Deutsches Krebsforschungszentrum | Cell culture of keratinocytes under non-differentiating conditions |
| GB201111244D0 (en) | 2011-06-30 | 2011-08-17 | Konink Nl Akademie Van Wetenschappen Knaw | Culture media for stem cells |
| US9752124B2 (en) | 2009-02-03 | 2017-09-05 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising the stem cells |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| FI20095355A0 (fi) | 2009-04-01 | 2009-04-01 | Helsingin Yliopisto | Regeneroituva aktiivinen matriisi ja sen käytöt |
| US20110076303A1 (en) | 2009-06-25 | 2011-03-31 | Tokuro Iwabuchi | Methods for Screening for Anti-Graying Agents on the Basis of AFF-4 |
| US20110130711A1 (en) | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
| WO2012000180A1 (zh) | 2010-06-30 | 2012-01-05 | Chen Jinxi | 一种皮肤组织细胞聚合物的制备方法及其用途 |
| GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| EP2771454B1 (en) | 2011-10-27 | 2019-07-24 | Universität Leipzig | Method for deriving melanocytes from the hair follicle outer root sheath and preparation for grafting |
| JP6186997B2 (ja) | 2012-08-07 | 2017-08-30 | 日油株式会社 | 塗布型帯電防止剤 |
| US9655930B2 (en) | 2012-10-01 | 2017-05-23 | Aderans Research Institute, Inc. | Compositions and methods for producing reconstituted skin |
| US20140106447A1 (en) | 2012-10-12 | 2014-04-17 | Mimedx Group, Inc. | Compositions and methods for recruiting stem cells |
| CA3184040A1 (en) | 2013-03-14 | 2014-10-02 | The Brigham And Women's Hospital, Inc. | Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor |
| US9592257B2 (en) | 2013-10-11 | 2017-03-14 | MWV Cell, LLC | Complete human skin organ generated from culture-expanded cells |
| CN103550828B (zh) * | 2013-10-17 | 2016-01-27 | 中国科学院动物研究所 | 一种基于毛囊干细胞和硅凝胶敷料的皮肤重建方法 |
| TWI548413B (zh) | 2014-11-07 | 2016-09-11 | 國立臺灣大學 | 誘導毛囊新生的皮膚萃取物、組合物及其用途 |
-
2015
- 2015-11-30 US US14/954,335 patent/US10926001B2/en active Active
- 2015-12-01 EA EA201791125A patent/EA201791125A1/ru unknown
- 2015-12-01 NZ NZ755260A patent/NZ755260A/en unknown
- 2015-12-01 CA CA2969707A patent/CA2969707C/en active Active
- 2015-12-01 GB GB1710646.9A patent/GB2549872A/en not_active Withdrawn
- 2015-12-01 EP EP15865131.5A patent/EP3227431B1/en active Active
- 2015-12-01 KR KR1020217010934A patent/KR20210043024A/ko not_active Ceased
- 2015-12-01 KR KR1020177017887A patent/KR20170098844A/ko not_active Ceased
- 2015-12-01 NZ NZ733433A patent/NZ733433A/en unknown
- 2015-12-01 BR BR112017011808A patent/BR112017011808A2/pt not_active Application Discontinuation
- 2015-12-01 CR CR20170296A patent/CR20170296A/es unknown
- 2015-12-01 KR KR1020187036618A patent/KR20180136587A/ko not_active Ceased
- 2015-12-01 JP JP2017530217A patent/JP6791854B2/ja active Active
- 2015-12-01 AU AU2015355187A patent/AU2015355187C1/en active Active
- 2015-12-01 KR KR1020187036619A patent/KR20180136588A/ko not_active Ceased
- 2015-12-01 CN CN201580075326.3A patent/CN107250348B/zh active Active
- 2015-12-01 MY MYPI2017701990A patent/MY184931A/en unknown
- 2015-12-01 GB GB201902819A patent/GB2569056B/en active Active
- 2015-12-01 WO PCT/US2015/063114 patent/WO2016089825A1/en not_active Ceased
- 2015-12-01 EP EP24181160.3A patent/EP4438128A3/en active Pending
- 2015-12-01 SG SG10201914058QA patent/SG10201914058QA/en unknown
- 2015-12-01 HK HK18104680.7A patent/HK1250515A1/zh unknown
- 2015-12-01 KR KR1020197028100A patent/KR20190111167A/ko not_active Ceased
- 2015-12-01 SG SG11201704502RA patent/SG11201704502RA/en unknown
- 2015-12-01 MX MX2017007243A patent/MX2017007243A/es unknown
-
2017
- 2017-05-31 PH PH12017501009A patent/PH12017501009B1/en unknown
- 2017-06-01 IL IL252613A patent/IL252613B/en unknown
- 2017-06-05 MX MX2023001655A patent/MX2023001655A/es unknown
- 2017-06-07 ZA ZA2017/03907A patent/ZA201703907B/en unknown
- 2017-06-30 CO CONC2017/0006640A patent/CO2017006640A2/es unknown
- 2017-07-14 US US15/650,656 patent/US20180154043A1/en not_active Abandoned
- 2017-07-14 US US15/650,659 patent/US11266765B2/en active Active
-
2018
- 2018-10-19 US US16/165,169 patent/US11000629B2/en active Active
-
2019
- 2019-01-16 JP JP2019004921A patent/JP2019088299A/ja active Pending
- 2019-10-02 AU AU2019240603A patent/AU2019240603B2/en active Active
-
2020
- 2020-07-30 JP JP2020129610A patent/JP2020182880A/ja active Pending
-
2021
- 2021-05-21 US US17/326,734 patent/US11338060B2/en active Active
- 2021-10-21 IL IL287488A patent/IL287488B2/en unknown
-
2022
- 2022-04-19 US US17/723,748 patent/US11596714B2/en active Active
-
2023
- 2023-02-03 US US18/164,308 patent/US12465669B2/en active Active
- 2023-05-08 AU AU2023202857A patent/AU2023202857A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017006640A2 (es) | Metodos para el desarrollo y uso de unidades de micro-agregado de funcion celular polarizada en aplicaciones de tejido usando lgr4, lgr5 y lgr 6 que expresan celulas madre epiteliales | |
| PH12021550307A1 (en) | T Cell Receptor Constructs And Uses Thereof | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| MX2015000990A (es) | Analogos del glucagon. | |
| MX2015014408A (es) | Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico. | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| CL2018002113A1 (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipo de cancer (divisonal solicitud 201800545) | |
| MX2016010998A (es) | Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados. | |
| CY1120488T1 (el) | Υγρη φαρμακευτικη συνθεση | |
| MX2019012849A (es) | Metodos de tratamiento con polipeptidos del dominio extracelular del cd80. | |
| CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
| ZA202503388B (en) | Semaglutide in medical therapy | |
| MX2019005160A (es) | Formulacion farmaceutica. | |
| MX2016010215A (es) | Composiciones y metodos de tratamiento y prevencion de degeneracion macular. | |
| CO2017001903A2 (es) | Entrega coordinada del tratamiento del epoc | |
| AR113450A1 (es) | Vectores adenovirales competentes en la replicación | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| UY36150A (es) | Derivados de naftiridinadiona | |
| CO6592047A2 (es) | Formulación tópica oftálmica de péptidos | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| BR112017006918A2 (pt) | formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares | |
| Harvard et al. | Measurable definitions of ankylosing spondylitis management recommendations are needed for use in observational studies | |
| Yuan et al. | Integrated therapy on residual tumor after palliative operation using dual-phase drug releasing electrospun fibrous scaffolds | |
| CY1124859T1 (el) | Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων | |
| AR112754A1 (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE a-ENaC Y MÉTODOS DE USO |